Cargando…
Doxorubicin and Varlitinib Delivery by Functionalized Gold Nanoparticles Against Human Pancreatic Adenocarcinoma
The aim of this study was to develop drug delivery nanosystems based on pegylated gold nanoparticles (PEGAuNPs) for a combination against pancreatic cancer cells. Doxorubicin and varlitinib, an anthracycline and a tyrosine kinase inhibitor respectively, were conjugated with gold nanoparticles. The s...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920992/ https://www.ncbi.nlm.nih.gov/pubmed/31652942 http://dx.doi.org/10.3390/pharmaceutics11110551 |
_version_ | 1783481061015027712 |
---|---|
author | Coelho, Sílvia Castro Reis, Daniel Pires Pereira, Maria Carmo Coelho, Manuel A. N. |
author_facet | Coelho, Sílvia Castro Reis, Daniel Pires Pereira, Maria Carmo Coelho, Manuel A. N. |
author_sort | Coelho, Sílvia Castro |
collection | PubMed |
description | The aim of this study was to develop drug delivery nanosystems based on pegylated gold nanoparticles (PEGAuNPs) for a combination against pancreatic cancer cells. Doxorubicin and varlitinib, an anthracycline and a tyrosine kinase inhibitor respectively, were conjugated with gold nanoparticles. The systems were characterized, after synthesis, regarding their size, stability and morphology. An efficient conjugation of doxorubicin and varlitinib with PEGAuNPs was revealed. The cytotoxicity effect induced by the combination of the nanoconjugates was investigated in pancreatic cancer cell lines. Doxorubicin and varlitinib conjugated with PEGAuNPs revealed a combined effect to decrease the cell survival of the cancer line S2-013s, while reducing the drugs’ toxicity for the healthy pancreatic cells hTERT-HPNE. This study highlights the promising potential of PEGAuNPs for targeted delivery of therapeutic drugs into human cells, enhancing the antitumor growth-inhibition effect on cancer cells, and decreasing the toxicity against normal cells. In cancer therapy, the present approach based on PEGAuNP functionalization can be further explored to increase drug targeting efficiency and to reduce side effects. |
format | Online Article Text |
id | pubmed-6920992 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69209922019-12-24 Doxorubicin and Varlitinib Delivery by Functionalized Gold Nanoparticles Against Human Pancreatic Adenocarcinoma Coelho, Sílvia Castro Reis, Daniel Pires Pereira, Maria Carmo Coelho, Manuel A. N. Pharmaceutics Article The aim of this study was to develop drug delivery nanosystems based on pegylated gold nanoparticles (PEGAuNPs) for a combination against pancreatic cancer cells. Doxorubicin and varlitinib, an anthracycline and a tyrosine kinase inhibitor respectively, were conjugated with gold nanoparticles. The systems were characterized, after synthesis, regarding their size, stability and morphology. An efficient conjugation of doxorubicin and varlitinib with PEGAuNPs was revealed. The cytotoxicity effect induced by the combination of the nanoconjugates was investigated in pancreatic cancer cell lines. Doxorubicin and varlitinib conjugated with PEGAuNPs revealed a combined effect to decrease the cell survival of the cancer line S2-013s, while reducing the drugs’ toxicity for the healthy pancreatic cells hTERT-HPNE. This study highlights the promising potential of PEGAuNPs for targeted delivery of therapeutic drugs into human cells, enhancing the antitumor growth-inhibition effect on cancer cells, and decreasing the toxicity against normal cells. In cancer therapy, the present approach based on PEGAuNP functionalization can be further explored to increase drug targeting efficiency and to reduce side effects. MDPI 2019-10-24 /pmc/articles/PMC6920992/ /pubmed/31652942 http://dx.doi.org/10.3390/pharmaceutics11110551 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Coelho, Sílvia Castro Reis, Daniel Pires Pereira, Maria Carmo Coelho, Manuel A. N. Doxorubicin and Varlitinib Delivery by Functionalized Gold Nanoparticles Against Human Pancreatic Adenocarcinoma |
title | Doxorubicin and Varlitinib Delivery by Functionalized Gold Nanoparticles Against Human Pancreatic Adenocarcinoma |
title_full | Doxorubicin and Varlitinib Delivery by Functionalized Gold Nanoparticles Against Human Pancreatic Adenocarcinoma |
title_fullStr | Doxorubicin and Varlitinib Delivery by Functionalized Gold Nanoparticles Against Human Pancreatic Adenocarcinoma |
title_full_unstemmed | Doxorubicin and Varlitinib Delivery by Functionalized Gold Nanoparticles Against Human Pancreatic Adenocarcinoma |
title_short | Doxorubicin and Varlitinib Delivery by Functionalized Gold Nanoparticles Against Human Pancreatic Adenocarcinoma |
title_sort | doxorubicin and varlitinib delivery by functionalized gold nanoparticles against human pancreatic adenocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920992/ https://www.ncbi.nlm.nih.gov/pubmed/31652942 http://dx.doi.org/10.3390/pharmaceutics11110551 |
work_keys_str_mv | AT coelhosilviacastro doxorubicinandvarlitinibdeliverybyfunctionalizedgoldnanoparticlesagainsthumanpancreaticadenocarcinoma AT reisdanielpires doxorubicinandvarlitinibdeliverybyfunctionalizedgoldnanoparticlesagainsthumanpancreaticadenocarcinoma AT pereiramariacarmo doxorubicinandvarlitinibdeliverybyfunctionalizedgoldnanoparticlesagainsthumanpancreaticadenocarcinoma AT coelhomanuelan doxorubicinandvarlitinibdeliverybyfunctionalizedgoldnanoparticlesagainsthumanpancreaticadenocarcinoma |